Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: pertuzumab, Roche/Genentech/Chugai.

James Spicer1

  • 1Guy's Hospital, Department of Medical Oncology, 3rd Floor, New Guy's House, St Thomas Street, London SE1 7EH, UK. James.Spicer@gstt.nhs.uk

Current Opinion in Molecular Therapeutics
|July 22, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dendrimer-nanoparticle (DEP) delivery of cabazitaxel (DEP-cabazitaxel): A first-in-human phase 1/2 trial in patients with advanced solid tumours.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.

Nature cancer·2026
Same author

AllergoOncology: Emerging Translational and Clinical Significance of Basophils and Mast Cells in Cancer.

Clinical and translational allergy·2026
Same author

Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer.

Radiology·2026
Same author

AllergoOncology in Review: Harnessing Allergy in the Field of Oncology to Improve Patient Outcomes.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study.

Cancers·2025

Pertuzumab, a novel monoclonal antibody targeting HER2, is being developed for cancer treatment. This next-generation therapy is currently in phase II clinical trials.

Area of Science:

  • Oncology
  • Immunotherapy
  • Molecular Biology

Background:

  • Cancer treatment often involves targeted therapies.
  • Monoclonal antibodies have emerged as a significant class of targeted cancer drugs.
  • HER2-positive cancers represent a key area for therapeutic development.

Purpose of the Study:

  • To evaluate the potential of pertuzumab as a novel cancer therapeutic.
  • To investigate the efficacy and safety of pertuzumab in ongoing clinical trials.

Main Methods:

  • Pertuzumab, an anti-HER2 monoclonal antibody, is under development.
  • The drug is being investigated in phase II clinical trials.
  • Pertuzumab is designed as a next-generation therapy, building on existing treatments like trastuzumab.

Related Experiment Videos

Main Results:

  • Pertuzumab is a novel anti-HER2 monoclonal antibody.
  • The drug is currently progressing through phase II clinical trials.
  • Early development suggests potential for cancer treatment.

Conclusions:

  • Pertuzumab represents a promising next-generation therapeutic candidate for cancer.
  • Ongoing clinical trials will determine the full potential and application of pertuzumab.
  • The development of pertuzumab highlights advancements in targeted cancer immunotherapy.